Table 4.

Univariate and multivariate analysis of prognostic factors for overall survival in de novo AML patients

	Whole AML patients		Non-M3 AML patients
	Hazard ratio (95%CI)	P	Hazard ratio (95%CI)	P
Univariate analysis
Age(<60y/≥60y)	3.242 (1.663–6.308)	0.001	3.268 (1.590–6.718)	0.001
WBC(<30 × 109/L /≥30 × 109/L)	2.216 (1.187–4.139)	0.013	2.242 (1.171–4.293)	0.015
Karyotypic classifications
(Favorable/Intermediate)	3.127 (1.071–9.130)	0.037	2.681 (0.628–11.452)	0.183
(Favorable/Poor)	8.836 (2.737–28.528)	0.000	7.604 (1.670–34.625)	0.009
(Favorable and intermediate/Poor)	3.705(1.775–7.736)	0.000	3.257 (1.555–6.821)	0.002
2Ig B7-H3 mRNA expression (Low/High)	2.352 (1.245–4.444)	0.008	1.894 (0.989–3.625)	0.054
B7-H3 membrane protein expression (Low/High)	1.776 (0.957–3.296)	0.069	1.975 (1.037–3.764)	0.038
NPM1 mutation (Wild-type/Mutant)	0.321 (0.113–0.915)	0.033	0.261 (0.091–0.753)	0.013
FLT3-ITD mutation (Wild-type/Mutant)	1.973 (0.926–4.205)	0.078	1.956 (0.884–4.326)	0.098
TP53 mutation (Wild-type/Mutant)	6.346 (2.042–19.716)	0.001	6.204 (1.972–19.516)	0.002
CR (No/Yes)	0.146 (0.068–0.314)	0.000	0.180 (0.082–0.395)	0.000
Multivariate
2Ig B7-H3 mRNA expression (Low/High)	1.581 (0.660–3.785)	0.304	1.724 (0.702–4.236)	0.235
Total B7-H3 membrane protein expression (Low/High)	1.896 (0.858–4.191)	0.114	1.334 (0.557–3.193)	0.518
TP53 mutation (Wild-type/Mutant)	9.291 (1.994–43.298)	0.005	8.027 (1.615–39.896)	0.011
CR (No/Yes)	0.124 (0.044–0.350)	0.000	0.162 (0.057–0.457)	0.001

Abbreviations: AML = acute myeloid leukemia; non-M3 AML = non-acute promyelocytic leukemia in AML; WBC = white blood cells; CR = complete remission.